With over 65 years combined experience, we have a long track record of delivering timely solutions for our clients.
At Odelle Technology, we connect innovators with the people who make the real decisions — NHS commissioners, EU payers, health insurers, HTA advisors, and procurement leaders. These are the individuals who determine whether a new health technology will be adopted, reimbursed, or scaled.
Why Early Payer Engagement Determines Reimbursement Success
Technologies rarely fail because of weak clinical evidence.
They fail because they are misaligned with funding architecture.
Structured payer engagement enables:
• Budget Impact Analysis (BIA) validation
• Cost-Utility and cost-consequence model refinement
• Coding pathway alignment (HRG, DRG, OPS/EBM, CCAM, LPPR)
• Comparator positioning under HTA scrutiny
• Procurement feasibility assessment
• Evidence gap identification before formal rejection
• Investor-grade reimbursement validation
This is not market research.
It is pre-submission system testing.
We organise interviews and strategic sessions with:
United Kingdom
- NHS Integrated Care Systems (ICS), CFOs, NICE assessors, AHSNs
France
- CNEDiMTS experts, PECAN evaluators, ARS decision-makers
Germany
- Statutory health insurers (GKV), NUB stakeholders, OPS/EBM coders
Spain
- Regional HTA bodies (CatSalut, SERMAS, Andalusia), Consorcio procurement leads
Italy
- AIFA, Agenas, regional procurement managers (Lombardy, Emilia-Romagna, Veneto)
Sweden & Belgium
- TLV, KCE, RIZIV-Mutualités, hospital-based payers
Austria, Portugal, Ireland
- Hospital procurement and payer groups across regional health authorities
Targeted Stakeholder Recruitment
- NHS commissioners, CFOs, EU payers, and HTA stakeholders
- GDPR-compliant recruitment with consent and incentives if appropriate
Interview & Research Techniques
- 1:1 depth interviews (virtual or in-person)
- Co-creation workshops and value testing
- Cognitive interviews and comparator testing
- Payer focus groups by country or region
- Exit interviews following HTA rejection or pilot completion
- Journey mapping and care pathway validation
- Observational research (pilot or early implementation studies)
Full Research Support
- Custom screeners and discussion guides
- Scheduling, logistics, transcription, and moderation
- Thematic analysis and executive-level summary reports
- Online presentation of insights to boards, pricing teams, or investors
Use Cases
- Pre-NICE HTE or Early Value Assessment
- PECAN readiness testing in France
- LPPR or CNEDiMTS submission strategy
- DiGA or NUB dossier development in Germany
- Regional payer adoption planning in Spain or Italy
- Validation of cost-consequence assumptions before HTA
- Procurement and pricing alignment for ICS/NHS tendering
How It’s Delivered
- Stakeholder recruitment (commissioners, payers, HTA advisors)
- Interview moderation and insight synthesis
- Presentation of findings with actionable recommendations
- Post-meeting strategy support and follow-up
Trusted by Innovators Across Europe
Our work is grounded in payer logic, reimbursement system science, and HTA methodology — not generic market research. We align all engagements with:
- NICE HTA Methods & BIA Templates
- PECAN and Forfait Innovation guidance (France)
- EBM, OPS, and NUB rules (Germany)
- DiGA and LPPR dossier evidence requirements
- KCE, TLV, HAS, ZIN and EU HTA21 frameworks
Ready to Speak with Decision-Makers?
Whether you’re planning an HTA submission, building a DiGA dossier, or validating pricing for the NHS, we help you engage the right stakeholders at the right time.
Contact us to request a tailored engagement proposal.